US · Healthcare · Diagnostics & Research
EPS came in at 0.02 against a street estimate of -0.10 — a beat of 120.0%.
Analysts rate Adaptive Biotechnologies Corp a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $30.21.
CONFIDENT MRD revenue +49% ex-milestones on 43% clinical volume growth. Raised FY26 guidance to $268–$278M. Announced separation of Immune Medicine. Raised $340M convertible, retired debt. Tracking to positive EBITDA/FCF by year-end. Q2 2026 No regional breakdown provided. Analysts pressed on multiple myeloma saturation (pushback: only 17% penetrated), ASP path to $1,400 (reassured by payer actions), and serial testing upside (confirmed left out of guide). Management confident in heme runway and disciplined on M&A. 2026-07-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| Viking Global Investors LP | 18.79% |
| BlackRock Inc | 9.49% |
| Vanguard Capital Management, LLC | 4.01% |
| Wellington Management Company LLP | 3.70% |
| Vanguard Portfolio Management, LLC | 3.43% |
| D. E. Shaw & Co LP | 2.90% |
| Westfield Capital Management Company, L.P. | 2.67% |
| Geode Capital Management, LLC | 2.28% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $83,902 thousand, down from $93,973 thousand in the third quarter of 2025. • Nine-month 2026 reven | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue was $83.9 million, down 11% year over year. Excluding Genentech Agreement revenue, revenue increased 39%. • MRD r | 2026-11-04 |
| Quarterly report · Q2 2026 ADAPTIVE BIOTECHNOLOGIES CORPORATION – 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Revenue (6 months): $142.4 million, up 2 | 2026-08-04 |
| Results announced · Q3 2026 ADAPTIVE BIOTECHNOLOGIES Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $71.6 million, up 22% year-over-year • MRD Revenue: $ | 2026-07-29 |
| Material agreement · Q2 2026 ADAPTIVE BIOTECHNOLOGIES CORPORATION – 8-K SUMMARY HEADLINE NUMBERS • $345 million in 0% Convertible Senior Notes issued on June 22, 2026, due July | 2026-06-22 |
| Company announcement · Q2 2026 ADAPTIVE BIOTECHNOLOGIES CORPORATION - 8-K SUMMARY HEADLINE NUMBERS • Company announced intention to offer $250 million in aggregate principal amoun | 2026-06-15 |
| Shareholder vote results · Q2 2026 ADAPTIVE BIOTECHNOLOGIES CORPORATION – 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 5, 2026 • Three proposals presented to sh | 2026-06-09 |
| Quarterly report · Q1 2026 ADAPTIVE BIOTECHNOLOGIES CORPORATION – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Quarterly Revenue: $70.9 million (Q1 2026) vs. $52.4 million (Q1 | 2026-05-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Full-year 2026 MRD revenue guidance raised to $276 million–$286 million Adaptive Biotechnologies reported a stronger-than-expected third quarter, reaching company-wide profitability. Revenue was $83.9 million, down 11% year over year because the prior-year perio | 2026-11-04 |
| Raises full year 2026 MRD revenue guidance to $268-$278 million range Adaptive Biotechnologies reported strong Q2 2026 results with total revenue of $71.6 million, up 22% year-over-year. The company's core MRD (Minimal Residual Disease) business performed exce | 2026-07-29 |
| Raises full year 2026 MRD revenue guidance to $260-$270 million range Adaptive Biotechnologies reported strong Q1 2026 results with total revenue of $70.9 million, up 35% year-over-year. The company's flagship MRD (Minimal Residual Disease) business drove perf | 2026-05-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Adaptive Biotechnologies Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.